Dr. Jorge Alvar will be a Keynote speaker at ALIVE 2024 giving the opening ceremony lecture: Control of visceral leishmaniasis: successes, risks and expectations

A Pioneer in the Fight Against Leishmaniasis

Welcome to the life and work of Dr. Jorge Alvar, a renowned figure in the world of medical research, specifically in the battle against Leishmaniasis. Dr. Alvar’s upcoming keynote lecture at ALIVE 2024, set in the picturesque city of Nice from April 18-20, 2024, is not just an event – it’s an insightful rendezvous with one of the most distinguished minds in tropical medicine.

His extensive career, from his early days at the Institute of Health Carlos III to his impactful role at the Drugs for Neglected Disease initiative (DNDi) in Geneva, has been marked by relentless dedication to combating neglected tropical diseases. With over 40 years of experience, his extensive list of publications has garnered more than 26,000 citations, and he boasts an h-index of 69. Additionally, he holds membership in the prestigious Royal Academy of Medicine of Spain.

Dr. Alvar's Journey: From Local Scientist to Global Health Crusader

In the realm of tropical medicine, few names resonate as profoundly as that of Dr. Jorge Alvar. His journey, originating from the prestigious halls of the University of Madrid, where he earned his medical degree and PhD, has been nothing short of extraordinary. Dr. Alvar’s passion for combating parasitic diseases led him to further his expertise with a master’s degree in Malaria & Environmental Health from Carabobo University, Venezuela, and a diploma in Tropical Medicine & Parasitology from Hamburg, Germany.

His early career saw him immersed in the world of parasitology and public health, working diligently at the Institute of Health Carlos III. Here, Dr. Alvar not only honed his skills as a scientist but also emerged as a leader, eventually heading the Department of Parasitology. His tenure was marked by significant strides in confronting parasitic epidemics and establishing a public health laboratory in Equatorial Guinea, a testament to his dedication to improving global health.

The turn of the millennium brought new challenges and opportunities for Dr. Alvar. In 2000, he assumed the role of Director of the National Centre of Tropical Medicine. But perhaps his most notable contribution to global health came with his role in the Leishmaniasis World Program at the World Health Organization (WHO). There, he spearheaded strategic plans and control programs in East Africa and South Asia, tackling the disease head-on.

Dr. Alvar’s expertise and impact extended beyond organizational boundaries when he joined the DNDi in Geneva. As the head, and later Senior Adviser, of the drug development program for Leishmaniasis, he played a pivotal role in advancing research and treatment for this neglected disease. His efforts have not gone unnoticed; his research in epidemiology and diagnosis of Leishmaniasis has earned him numerous awards and recognition, including an impressive citation record and a high h-index factor.

Throughout his career, Dr. Alvar has been a symbol of optimism and innovation in the fight against Leishmaniasis. His work has spanned continents, involving him in over 30 research projects or clinical trials and bringing his expertise to communities in dire need. As a member of the Royal Academy of Medicine of Spain, his contributions to medical science and public health continue to inspire and drive progress in the field.

As we look forward to his keynote lecture at ALIVE 2024, it’s clear that Dr. Alvar’s journey is far more than a career; it’s a lifelong mission to eradicate one of the world’s most debilitating diseases. His story is not just one of scientific achievement but of profound human impact, a narrative that continues to unfold and inspire those dedicated to the field of tropical medicine and global health​​.

Tackling Neglected Tropical Diseases: The DNDi Approach

In the landscape of global health, the Drugs for Neglected Disease initiative (DNDi) stands as a towering testament to innovative and humanitarian approaches to medicine. Dr. Jorge Alvar’s involvement with DNDi marks a crucial chapter in his illustrious career, reflecting a profound commitment to addressing diseases often overlooked by mainstream medical research.

DNDi emerged from a noble vision: to bring much-needed attention and resources to the fight against neglected tropical diseases (NTDs). It was founded in 2003, following a decision by Médecins Sans Frontières to allocate part of their Nobel Peace Prize funds to this cause. This initiative signified a paradigm shift in how the medical community approached NTDs, including Leishmaniasis, which affects over a billion people, predominantly in impoverished communities.

Under Dr. Alvar’s guidance, DNDi focused on developing treatments that are not only effective but also accessible and easy to administer. This approach is crucial in areas where medical resources are scarce and the burden of disease is high. The initiative’s work, recognized through prestigious awards like the Princesa de Asturias Award for International Cooperation, underscores the impact of collaborative, non-profit research in changing the global health landscape.

Dr. Alvar’s role in DNDi was instrumental in steering the organization towards groundbreaking research and development. His leadership helped bridge the gap between scientific innovation and practical, life-saving applications in the field. The initiative’s success is a testament to Dr. Alvar’s vision of a world where the scourge of NTDs is a thing of the past, a vision that he continues to pursue with relentless passion and dedication.

A Decade of Progress and Challenge

Over the past decade, under the stewardship of Dr. Jorge Alvar and organizations like DNDi, there has been significant progress in combating Neglected Tropical Diseases (NTDs). This journey, however, is marked by both remarkable achievements and ongoing challenges.

The concerted international effort against NTDs has resulted in substantial strides forward. For instance, the past ten years have seen 500 million people no longer requiring NTD control programs. Diseases like lymphatic filariasis and trachoma have been eliminated as public health problems in several countries. The success stories extend to leishmaniasis in Southeast Asia and the near-eradication of Guinea worm disease.

However, these triumphs exist alongside persistent challenges. NTDs, closely linked to poverty, continue to demand substantial investment in research and healthcare infrastructure strengthening. Dr. Alvar stresses the critical need for continued focus on these diseases, underscoring their intimate connection to impoverished conditions and remote regions. The fight against NTDs is not just a medical challenge but also a socio-economic one, requiring holistic approaches and sustained efforts.

Moreover, the emergence of new challenges such as COVID-19 has disrupted control programs and funding, highlighting the fragility of progress and the need for resilience in public health initiatives. Dr. Alvar’s insights into these complex dynamics will be pivotal in his upcoming lecture at ALIVE 2024, offering a comprehensive view of the past achievements and future directions in the battle against NTDs​​​​.

The Broader Impact of Climate Change and Global Dynamics

In the intricate tapestry of global health, the impact of broader factors like climate change and population dynamics becomes increasingly evident, a theme that Dr. Jorge Alvar has often highlighted in his work. The phenomenon known as the “Great Acceleration,” driven by population growth and its associated activities, disproportionately affects developing countries. These countries, already burdened with neglected tropical diseases (NTDs), now face additional challenges posed by climate change.

The rise in global temperatures, now seemingly unstoppable, has immediate health implications. It not only exacerbates malnutrition and increases the incidence of violent episodes but also influences the spread of NTDs. Diseases once confined to tropical and subtropical zones are now encroaching upon new areas, including temperate regions. A stark example is the Aedes albopictus mosquito, the carrier of diseases like chikungunya and dengue, which has expanded its habitat to southern Europe.

Furthermore, environmental degradation is forcing wildlife, potential reservoirs of various pathogens, closer to human habitats. This proximity increases the risk of new zoonoses, diseases transmitted from animals to humans, a significant concern in tropical regions where 60% of emerging diseases are zoonotic in origin.

Dr. Alvar’s insights into these global dynamics underline the interconnected nature of NTDs, environmental change, and public health. His perspective sheds light on the necessity of a multidimensional approach to health, one that integrates environmental and social factors into the fight against diseases like Leishmaniasis​​.

Innovations in Treatment and Healthcare

In the realm of medical research and treatment, innovation is the key to progress. This is particularly true in the work of Dr. Jorge Alvar, whose contributions to Leishmaniasis treatment have been groundbreaking. His approach has not only improved existing treatments but has also introduced new, more effective methods.

Under Dr. Alvar’s guidance, the treatment of Leishmaniasis, especially in patients co-infected with HIV, has seen remarkable improvements. Traditional treatment methods, once only moderately effective, have evolved into more efficient regimes, dramatically increasing the success rate. These advancements are a testament to Dr. Alvar’s deep understanding of the disease and his commitment to finding more effective solutions.

One of the hallmarks of his approach is the development of treatments that are easier to administer. The move from injectables to oral medications, for example, represents a significant step forward in patient care. This shift not only reduces the risks associated with injections but also makes treatment more accessible, especially in remote areas where medical resources are scarce.

Dr. Alvar’s innovative strategies in tackling Leishmaniasis are expected to be a major highlight of his keynote speech at ALIVE 2024. His work exemplifies the importance of continuous research and adaptation in the field of tropical medicine and offers hope for better treatment methods for those affected by this disease​​.

Conclusion: The Road Ahead

As we conclude this exploration of Dr. Jorge Alvar’s significant contributions to the field of tropical medicine, particularly in combating Leishmaniasis, it becomes evident that his journey is a beacon of hope and a source of inspiration. His accomplishments, from groundbreaking research to innovative treatment methods, have not only advanced medical science but also transformed the lives of countless individuals affected by neglected tropical diseases.

Looking forward to his keynote lecture at ALIVE 2024, it’s clear that Dr. Alvar’s insights will be invaluable to both veterinarians and researchers. His unique perspective, blending scientific expertise with a deep understanding of the social and environmental factors affecting health, makes his address a must-attend event for professionals in the field.

Join ALIVE 2024

As we draw inspiration from Dr. Jorge Alvar’s journey and achievements, we invite you to join us at ALIVE 2024. This conference presents a unique opportunity to engage with leading minds in the field of Leishmaniosis research and treatment. Whether you are a veterinarian eager to learn about the latest developments in combating this disease, or a researcher seeking insights into innovative treatment methodologies, ALIVE 2024 is the place to be.

Register now to be part of this enlightening experience in Nice. Engage with experts, share knowledge, and contribute to the global effort in tackling Leishmaniosis and other neglected tropical diseases. Let’s come together to make a difference in the world of tropical medicine.


  1. The Lancet Global Health Article:"New Tools and Strategies for Tuberculosis Diagnosis, Care, and Elimination," The Lancet Global Health, 2021. Available at: The Lancet.
  2. Real Instituto Elcano Blog Post:"Un premio a la investigación terapéutica en favor de los más pobres," Real Instituto Elcano, 2023. Available at: Real Instituto Elcano.
  3. La Voz de Asturias Article:"Jorge Álvar: 'El modelo funciona, hemos desarrollado 12 medicamentos y tendremos 15 en 2030'," La Voz de Asturias, October 2023. Available at: La Voz de Asturias.
  4. Google Scholar Profile: Google Scholar profile of an individual researcher. Available at: Google Scholar.
  5. El País Article:"La Iniciativa para Enfermedades Desatendidas, premio Princesa de Asturias de Cooperación Internacional 2023," El País, June 2023. Available at: El País.